Annabel Samimy
Stock Analyst at Stifel Nicolaus
(4.78)
# 561
Out of 5,088 analysts
411
Total ratings
47.9%
Success rate
15.2%
Average return
Main Sectors:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Maintained: Hold | $55 | $41.84 | +31.45% | 32 | Oct 30, 2026 | |
| LGND Ligand Pharmaceuticals | Maintained: Buy | $350 | $317.33 | +10.30% | 11 | Oct 30, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $95 | $26.86 | +253.69% | 27 | Oct 29, 2026 | |
| RGNX REGENXBIO | Reiterated: Buy | $42 | $7.41 | +466.80% | 28 | Oct 21, 2026 | |
| EYPT EyePoint | Reiterated: Buy | $40 → $6 | $0.38 | +1,478.95% | 2 | Oct 20, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $70 → $84 | $54.54 | +54.02% | 12 | Oct 12, 2026 | |
| OCS Oculis Holding AG | Reiterated: Buy | $40 | $8.24 | +385.44% | 13 | Sep 28, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $35.01 | $10.14 | +245.26% | 5 | Sep 24, 2026 | |
| IVA Inventiva | Reiterated: Buy | $15 | $3.73 | +302.14% | 20 | Sep 23, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $90 | $21.94 | +310.21% | 9 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $13.81 | +117.23% | 25 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $7.52 | +126.06% | 27 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $230 → $275 | $207.83 | +32.32% | 42 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $250 | $151.58 | +64.93% | 9 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 | $21.24 | +144.82% | 13 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $6.22 | +350.16% | 6 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.14 | - | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.6054 | n/a | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2,450.00 | n/a | 3 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.863 | n/a | 19 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $4.65 | n/a | 13 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20.96 → $19.56 | $12.41 | n/a | 24 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $63 | $0.00615 | n/a | 6 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $15 | $1.75 | n/a | 4 | Jun 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $5 | $1.83 | n/a | 20 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $80 → $87 | $15.90 | n/a | 14 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $7.31 | n/a | 8 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $85.95 | n/a | 1 | Jan 13, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $12.15 | n/a | 1 | Dec 4, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $56 | $35.90 | n/a | 1 | Oct 18, 2011 |
Supernus Pharmaceuticals
Oct 30, 2026
Maintained: Hold
Price Target: $55
Current: $41.84
Upside: +31.45%
Ligand Pharmaceuticals
Oct 30, 2026
Maintained: Buy
Price Target: $350
Current: $317.33
Upside: +10.30%
Viking Therapeutics
Oct 29, 2026
Reiterated: Buy
Price Target: $95
Current: $26.86
Upside: +253.69%
REGENXBIO
Oct 21, 2026
Reiterated: Buy
Price Target: $42
Current: $7.41
Upside: +466.80%
EyePoint
Oct 20, 2026
Reiterated: Buy
Price Target: $40 → $6
Current: $0.38
Upside: +1,478.95%
MBX Biosciences
Oct 12, 2026
Reiterated: Buy
Price Target: $70 → $84
Current: $54.54
Upside: +54.02%
Oculis Holding AG
Sep 28, 2026
Reiterated: Buy
Price Target: $40
Current: $8.24
Upside: +385.44%
Eupraxia Pharmaceuticals Inc.
Sep 24, 2026
Reiterated: Buy
Price Target: $35.01
Current: $10.14
Upside: +245.26%
Inventiva
Sep 23, 2026
Reiterated: Buy
Price Target: $15
Current: $3.73
Upside: +302.14%
Structure Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $90
Current: $21.94
Upside: +310.21%
Aug 7, 2026
Reiterated: Buy
Price Target: $30
Current: $13.81
Upside: +117.23%
Aug 6, 2026
Reiterated: Buy
Price Target: $17
Current: $7.52
Upside: +126.06%
Aug 4, 2026
Reiterated: Buy
Price Target: $230 → $275
Current: $207.83
Upside: +32.32%
Jun 24, 2026
Reiterated: Buy
Price Target: $250
Current: $151.58
Upside: +64.93%
May 7, 2026
Reiterated: Buy
Price Target: $52
Current: $21.24
Upside: +144.82%
Jan 15, 2026
Reiterated: Buy
Price Target: $28
Current: $6.22
Upside: +350.16%
Dec 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $2.14
Upside: -
Apr 1, 2025
Reiterated: Buy
Price Target: $8
Current: $0.6054
Upside: n/a
Jan 8, 2025
Reiterated: Buy
Price Target: n/a
Current: $2,450.00
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $0.863
Upside: n/a
Aug 30, 2023
Reiterated: Hold
Price Target: $11
Current: $4.65
Upside: n/a
Nov 3, 2022
Reiterated: Buy
Price Target: $20.96 → $19.56
Current: $12.41
Upside: n/a
Oct 19, 2022
Downgraded: Hold
Price Target: $63
Current: $0.00615
Upside: n/a
Jun 30, 2022
Downgraded: Hold
Price Target: $5 → $15
Current: $1.75
Upside: n/a
May 6, 2021
Reiterated: Buy
Price Target: $6 → $5
Current: $1.83
Upside: n/a
Aug 9, 2018
Reiterated: Hold
Price Target: $80 → $87
Current: $15.90
Upside: n/a
Nov 7, 2016
Reiterated: Hold
Price Target: $7
Current: $7.31
Upside: n/a
Jan 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $85.95
Upside: n/a
Dec 4, 2013
Initiated Coverage: Buy
Price Target: $27
Current: $12.15
Upside: n/a
Oct 18, 2011
Rated: Buy
Price Target: $56
Current: $35.90
Upside: n/a